Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.55 |
| ▸ | HPN | P05981 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6054982 | 0.95 | VCAM1 (0.92) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8100563 | 0.95 | VCAM1 (0.90) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL7568308 | 0.92 | VCAM1 (1.00) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL3146663 | 0.91 | VCAM1 (0.83) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL25639629 | 0.90 | VCAM1 (0.81) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12012989 | 0.90 | VCAM1 (0.83) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL13260389 | 0.90 | VCAM1 (0.81) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8191857 | 0.88 | VCAM1 (0.79) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042606 | 0.88 | VCAM1 (0.81) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8258176 | 0.87 | VCAM1 (0.77) | VCAM1ALOX15HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| CN-110604820-B | Double-sensitive polymer-drug connector and preparation method and application thereof | 辽宁大学 | 2023-07-28 | — | — | CN | claimed |
| EP-4164619-A1 | TREATMENT METHODS AND FORMULATIONS | Curtin University (AU) | 2023-04-19 | — | — | EP | claimed |
| EP-4146179-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici SpA (IT) | 2023-03-15 | — | — | EP | claimed |
| CN-115776886-A | Compounds useful in the treatment of COVID-19 | 东佩制药股份公司 | 2023-03-10 | — | — | CN | claimed |
| CN-115491345-A | Application of small molecule compound in kidney-derived cell culture | 广州华越肾科再生医学科技有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-20220175758-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. | 2022-06-09 | — | — | US | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| CN-111434647-A | Polymorphic forms of probucol monosuccinate | 中国科学院上海药物研究所 | 2020-07-21 | — | — | CN | claimed |
| US-7687659-B2 | Process for the separation of probucol derivatives | SALUTRIA PHARMACEUTICALS LLC (US) | 2010-03-30 | — | — | US | claimed |
| EP-1874725-A2 | PROCESS FOR THE SEPARATION OF PROBUCOL DERIVATIVES | Atherogenics, Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| US-20060258883-A1 | Process for the separation of probucol derivatives | CRABTREE ACQUISITION CO, LLC | 2006-11-16 | — | — | US | claimed |
| WO-2006116038-A2 | PROCESS FOR THE SEPARATION OF PROBUCOL DERIVATIVES | ATHEROGENICS, INC. (US) | 2006-11-02 | — | — | WO | claimed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | disclosed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003039231-A2 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | ATHEROGENICS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175758-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | SLC10A1, LIPC, FABP1 | VCAM1 3370/4885ALOX15 246/4885HPN 390/4885 |
| US-20060258883-A1 | Process for the separation of probucol derivatives | LIPC, CEL, APOB | VCAM1 2845/4885ALOX15 1470/4885HPN 427/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | VCAM1 4649/4885ALOX15 1829/4885HPN 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.